CARMIGNAC PORTFOLIO MERGER ARBITRAGE PLUS F GBP ACC





LOWE	R RISK			HIGHER RISK			
1	2	3*	4	5	6	7	

LUXEMBOURG SICAV SUB-FUND

LU2601234169 Monthly Factsheet - 31/05/2024

INVESTMENT OBJECTIVE


Carmignac Portfolio Merger Arbitrage Plus is a UCITS fund, following an alternative investment strategy that seeks to benefit from the price discontinuities ("arbitrage") of the shares related to merger and acquisition transactions. The Fund invests in officially announced M&A deals in the developed markets. The Fund seeks to achieve a positive absolute return over a 3-year investment horizon through capital growth.

Fund Management analysis can be found on P.3

PERFORMANCE

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).

FUND PERFORMANCE SINCE LAUNCH (Basis 100 - Net of fees)



CUMULATIVE AND ANNUALIZED PERFORMANCE (as of 31/05/2024 - Net of fees)

	Cumulative	Performance (%)	Annualised Performance (%)
	1 Year	Since 14/04/2023	Since 14/04/2023
F GBP Acc Hdg	5.60	4.74	4.18

ANNUAL PERFORMANCE (%) (Net of fees)

	2023
F GBP Acc Hdg	3.83







F. Cretin-Fumeron

S. Dieudonne

KEY FIGURES

Merger Arbitrage Exposure (1)	100.5%
Number of Strategies	42
Cash and Others	30.9%
Net Equity Exposure	70.3%

FUND

SFDR Fund Classification: Article 8

Domicile: Luxembourg **Fund Type:** UCITS **Legal Form:** SICAV

SICAV Name: Carmignac Portfolio

Fiscal Year End: 31/12

Subscription/Redemption: Daily

Order Placement Cut-Off Time: Before 13:30

(CET/CEST)

Fund Inception Date: 14/04/2023 Fund AUM: 143M€ / 155M\$ ⁽²⁾ Fund Currency: EUR

SHARE

Dividend Policy: Accumulation Date of 1st NAV: 14/04/2023 Base Currency: GBP Share class AUM: 52368£

NAV: 104.74£

FUND MANAGER(S)

Fabienne Cretin-Fumeron since 14/04/2023 Stéphane Dieudonné since 14/04/2023

OTHER ESG CHARACTERISTICS


Minimum % Taxonomy Alignment	. 0%
Minimum % Sustainable Investments	. 0%
Principal Advorse Impact Indicators	Vac



^{*} For the share class Carmignac Portfolio Merger Arbitrage Plus F GBP Acc Hdg. Risk Scale from the KID (Key Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time. (1) Sum of all the long equity exposures from the portfolio, the short book is excluded. (2) Exchange Rate EUR/USD as of 31/05/2024.

CARMIGNAC PORTFOLIO MERGER ARBITRAGE PLUS F GBP ACC HDG


MERGER ARBITRAGE EXPOSURE (%) (1)



TOP TEN - MERGER ARBITRAGE

Name	Country	Sector / Rating	%
HESS CORP	USA	Energy	8.3%
ENERPLUS CORP	Canada	Energy	4.9%
SOUTHWESTERN ENERGY CO	USA	Energy	4.1%
AXONICS INC	USA	Healthcare	3.9%
SHINKO ELECTRIC INDUSTRIES CO LTD	Japan	Information Technology	3.9%
ANSYS INC	USA	Information Technology	3.5%
PGS ASA	Norway	Energy	3.3%
ALTIUM LTD	Australia	Information Technology	3.1%
ENCAVIS AG	Germany	Utilities	3.1%
HASHICORP INC	USA	Information Technology	3.1%
Total			41.1%

MERGER ARBITRAGE RISK LEVEL




MERGER ARBITRAGE TYPE




MERGER ARBITRAGE NATURE





LONG SECTORIAL EXPOSURE



MAIN MERGERS & ACQUISITIONS OVER THE MONTH

Target	Buyer	Sector	Size (M€)	Country
MARATHON OIL CORP	CONOCOPHILLIPS	Energy	21082	USA
BANCO DE SABADELL SA	BANCO BILBAO VIZCAYA ARGENTARI	Financials	11586	Spain
ATLANTICA SUSTAINABLE INFRASTR	ENERGY CAPITAL PARTNERS LLC	Utilities	6818	United Kingdom
SQUARESPACE INC	PERMIRA HOLDINGS LLP	Information Technology	5958	USA
ALLETE INC	CANADA PENSION PLAN INVESTMENT BOARD, GLOBAL INFRASTRUCTURE MANAGEMENT LLC	Utilities	5166	USA



FUND MANAGEMENT ANALYSIS





- May was a difficult month for the strategy, with the HFRX Merger Arbitrage index down 0.8%.
- This was partly due to the increase in the DS Smith spread amid rumours of an offer for its potential buyer, International Paper, from Brazil's Suzano.
- Other spreads also rose in May, though without anything specific to point out: Hess, Ansys and Cerevel Therapeutics
- A few major deals were completed: Pioneer Natural Resources, SP Plus and MorphoSys
- It seems the resources freed up are being reallocated to some recently announced smaller deals, on which spread are fairly small.
- M&A activity is holding up well with 30 new deals announced in May for a total of \$114bn. Most of this growth is coming from Europe and Asia.
- Private Equity funds account for nearly half of all bidders in deals announced during the month.



PERFORMANCE COMMENTARY

- The Fund delivered a positive return.
- The main contributors were: Pioneer Natural Resources, SP Plus and MorphoSys
- The main hindrances were: Hess, Ansys and Cerevel Therapeutics
- We had no position on the DS Smith spread when rumours emerged about an offer for its potential buyer. Shortly after, though, we opened a small position when the risk-reward profile looked interesting.



OUTLOOK AND INVESTMENT STRATEGY

- The Fund's investment rate increased from 98% to 100% given the large number of deals closed in May.
- With 42 positions in the portfolio, diversification remains satisfactory.
- 2024 should see the M&A cycle pick up due to the stabilisation (or even reduction) in interest rates, the energy transition spreading to more sectors of the economy, private equity funds making a return, and Japanese stock markets undergoing regulatory change.
- The risk premium on the Merger Arbitrage strategy still offers investors some attractive returns, especially at a time when few deals are collapsing.



GLOSSARY

Active Management: An investment management approach where a manager aims to beat the market through research, analysis and their own judgement. See also Passive management.

Investment/net exposure rate: The investment rate constitutes the volume of assets invested expressed as a percentage of the portfolio. Adding the impact of the derivatives to this investment rate results in the net exposure rate, which corresponds to the real percentage of asset exposure to a certain risk. Derivatives can be used to increase the underlying asset's exposure (stimulation) or reduce it (hedging).

Merger Arbitrage Exposure: The Merger Arbitrage Exposure level refers to the equity long book of the portfolio, the short book used as coverage is excluded

Merger Arbitrage Risk: The risk level of each deal from the equity long book of the portfolio is assessed to determine the risk of deal failure. Ratings are based on our in-house methodology and rated between A and C, where A is the least risky and C is the highest risk.

Net asset value: Price of all units (in an FCP) or shares (in a SICAV).

SICAV: Société d'Investissement à Capital Variable (Open-ended investment company with variable capital)

ESG DEFINITIONS & METHODOLOGY

ESG: E for Environment, S for Social, G for Governance

ESG score Calculation: Only the Equity and Corporate Bond holdings of the fund considered. Overall Fund Rating calculated using MSCI Fund ESG Quality Score methodology: excluding cash and non ESG-rated holdings, performing a weighted average of the normalized weights of the holdings and the Industry-Adjusted Score of the holdings, multiplied by (1+Adjustment%) which consists of the weight of positively trending ESG ratings minus the weight of ESG Laggards minus the weight of negatively trending ESG ratings. For a detailed explanation see "MSCI ESG Fund Ratings Methodology", Section 2.3. Updated June 2021. https://www.msci.com/documents/1296102/15388113/MSCI+ESG+Fund+Ratings+Exec+Summary+Methodology.pdf/ec622acc-42a7-158f-6a47-ed7aa4503d4f?t=1562690846881.

Principal Adverse Impacts (PAI): Negative, material, or potentially material effects on sustainability factors that result from, worsen, or are directly related to investment choices or advice performed by a legal entity. Examples include GHG emissions and carbon footprint.

Sustainable Investments: The SFDR defines sustainable investment as an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

Taxonomy Alignment: In the context of an individual company, taxonomy alignment is defined as the proportion of a company's revenue that comes from activities that meet certain environmental criteria. In the context of an individual fund or portfolio, alignment is defined as the portfolio-weight weighted average taxonomy alignment of included companies. For more information, please follow this link:

https://ec.europa.eu/info/sites/default/files/business_economy_euro/banking_and_finance/documents/sustainable-finance-taxonomy-faq_en.pdf

CHARACTERISTICS

Date	Date of 1st	Day (fd)			Forton	5.0	Management fees		D. of comment	Minimum Initial	Single Year Performance (%)				
Share Class	NAV	Bloomberg	ISIN	Management Fee	Entry costs ⁽¹⁾	Exit costs ⁽²⁾	and other administrative or operating costs ⁽³⁾	Transaction costs ⁽⁴⁾	fees (5)	Subscription (6)	31.05.23-				31.05.19- 29.05.20
F EUR Acc	14/04/2023	CARMERF LX	LU2585801173	Max. 1%	_	_	1.25%	0.84%	20%	_	4.7	_	_	_	_
A EUR Acc	14/04/2023	CARARBA LX	LU2585801256	Max. 1.5%	Max. 1%	_	1.8%	0.84%	20%	_	4.2	_	_	_	_
F USD Acc Hdg	14/04/2023	CAPMAFU LX	LU2601233948	Max. 1%	_	_	1.25%	0.98%	20%	_	5.9	_	_	_	_
E GRP Acc Hdg	14/04/2023	CAPMARGIX	1112601234169	May 1%	_	_	1 25%	0.99%	20%	_	5.6	_	_	_	_

(1) of the amount you pay in when entering this investment. This is the most you will be charged. Carmignac Gestion doesn't charge any entry fee. The person selling you the product will inform you of

(2) We do not charge an exit fee for this product.
(3) of the value of your investment per year. This estimate is based on actual costs over the past year.
(4) of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the investments underlying the product. The actual amount varies depending on the

quantity we buy and sell.
(5) when the share class overperforms the Reference indicator during the performance period. It will be payable also in case the share class has overperformed the reference indicator but had a negative performance. Underperformance is clawed back for 5 years. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years, or since the product creation if it is less than 5 years.

(6) Please refer to the prospectus for the minimum subsequent subscription amounts. The prospectus is available on the website: www.carmignac.com.

MAIN RISKS OF THE FUND

EQUITY: The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization. ARBITRAGE RISK: Arbitrage seeks to benefit from such price differences (e.g. in markets, sectors, securities, currencies). If arbitrage performs unfavorably, an investment may lose its value and generate a loss for the Sub-Fund. RISK ASSOCIATED WITH THE LONG/SHORT STRATEGY: This risk is linked to long and/or short positions designed to adjust net market exposure. The fund may suffer high losses if its long and short positions undergo simultaneous unfavourable development in opposite directions. LIQUIDITY: Temporary market distortions may have an impact on the pricing conditions under which the Fund might be caused to liquidate, initiate or modify its positions.

The Fund presents a risk of loss of capital.



CARMIGNAC PORTFOLIO MERGER ARBITRAGE PLUS F GBP ACC HDG

IMPORTANT LEGAL INFORMATION

Source: Carmignac at 31/05/2024. Copyright: The data published in this presentation are the exclusive property of their owners, as mentioned on each page. From 01/01/2013 the equity index reference indicators are calculated net dividends reinvested. This document may not be reproduced, in whole or in part, without prior authorisation from the management company. This document does not constitute a subscription offer, nor does it constitute investment advice. Access to the Fund may be subject to restrictions with regard to certain persons or countries. The Fund is not registered in North America, in South America, in Asia nor is it registered in Japan. The Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Fund has not been registered under the US Securities Act of 1933. The Fund may not be offered or sold, directly or indirectly, for the benefit or on behalf of a U.S. person, according to the definition of the US Regulation S and/or FATCA. The Fund presents a risk of loss of capital. The risks and fees are described in the KID (Key Information Document). The Fund's prospectus, KIDs and annual reports are available at www.carmignac.com, or upon request to the Management Company. The KID must be made available to the subscriber prior to subscription. The Management Company can cease promotion in your country anytime. Investors have access to a summary of their rights in English on the following link at section 6: https://www.carmignac.com/en_US/article-page/regulatory-information-1788 - In Switzerland, the Fund's respective prospectuses, KIDs and annual reports are available at www.carmignac.com, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS and, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon. - In the United Kingdom, the Funds' respective prospectuses, KIDs and annual reports are available at www.carmignac.co.u.k, or upon request to the Management Company, o

